Gestational trophoblastic diseases: current trends and perspectives

Area of Science:

• Gynecology
• Oncology
• Genetics

Background:

• Gestational trophoblastic diseases (GTD) encompass a range of conditions, from hydatidiform mole to choriocarcinoma.
• Complete moles are typically diploid with paternal origin chromosomes, while partial moles are triploid with maternal and paternal sets.
• Early treatment involves suction evacuation, with chemotherapy used for persistent or advanced GTD based on prognostic scores.

Purpose of the Study:

• To investigate the underlying mechanisms of Gestational Trophoblastic Diseases (GTD) unique curability.
• To compare apoptosis induction and multidrug resistance gene expression between normal trophoblasts and GTD.
• To gain insights into chemoresistance in GTD.

Main Methods:

• Review of cytogenetic, molecular biology, and immunobiology studies on GTD.
• Comparative analysis of apoptosis and multidrug resistance gene expression in normal trophoblasts versus GTD.
• Correlation of findings with clinical outcomes and treatment responses.

Main Results:

• Most GTD cases, including hydatidiform mole and choriocarcinoma, demonstrate high curability with appropriate treatment.
• Cytogenetic analysis reveals distinct origins for complete (paternal) and partial (maternal/paternal) moles.
• Chemotherapy remains a cornerstone for persistent or aggressive GTD, guided by prognostic scoring.

Conclusions:

• Gestational trophoblastic diseases (GTD) exhibit remarkable curability, though the precise reasons remain under investigation.
• Understanding the molecular pathways of apoptosis and drug resistance in GTD is crucial for optimizing treatment.
• Further research into GTD's molecular biology may unlock novel therapeutic strategies and improve chemoresistance management.